Skip to content
Screener

Denali Therapeutics Inc. DNLI Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
uniQure logo
uniQureQURE
$249.12M+566,073%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-32.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$325.12M+42,455%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from sale of revenue participation right200,000
Proceeds from exercise of awards under equity incentive plans21,7004,652
Payments for finance lease right-of-use asset(38)(6,791)
Net cash provided by (used in) financing activities234,028(2,139)
Net decrease in cash, cash equivalents and restricted cash(3,796)(32,222)
Cash, cash equivalents and restricted cash at beginning of period208,432176,535
Cash, cash equivalents and restricted cash at end of period$204,636$144,313
Supplemental disclosures of cash flow information

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s financing cash flow?
Denali Therapeutics Inc. (DNLI) reported financing cash flow of $14.98M in Q2 2026.
How has Denali Therapeutics Inc.'s financing cash flow changed year-over-year?
Denali Therapeutics Inc.'s financing cash flow increased by 823.2% year-over-year, from $1.62M to $14.98M.
What is the long-term trend for Denali Therapeutics Inc.'s financing cash flow?
Over 3 years (2021 to 2025), Denali Therapeutics Inc.'s financing cash flow has grown at a 113.8% compound annual growth rate (CAGR), from $19.35M to $189.22M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Denali Therapeutics Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude